Industry Spotlight  |
Cell Therapy Development

In Conversation With… Marta Barisa, Senior Research Fellow at UCL

Edited by Ben Norris |
30 October 2023
Here, we speak to Marta Barisa, Senior Research Fellow at UCL, about switchable CAR-Ts and therapies for solid tumours.

Get your regular dose of industry news and announcements here, and keep up to date with our latest  spotlights and updates. 

Visit our Cell & Gene Portal to learn more about the latest research intspatial omics and its developmentsIf you’d like to learn more about Oxford Global’s upcoming Cell UK conference, click here to download an agenda or register your interest.

Speaker Biographies

Marta Barisa is a Senior Research Fellow at University College London, and works with the Experimental Paediatric Oncology Research Group and Allogeneic Immunotherapy Research Group at the Zayed Centre of UCL FOS ICH. She specialises in solid cancer immunotherapy development, and has a particular interest in paediatric solid tumours. Her research focuses on evaluating ways to target and re-polarise the solid tumour microenvironment, including approaches in radiotherapy, chemotherapy, checkpoint blockade, and antibody-dependent cellular cytotoxicity. Barisa’s work ranges from early-to-late stage cell therapy drug development, including gene engineering construct design, transduction process optimisations, cell signalling analysis, and scale-ups of both viral and cell therapy product manufacture. A key focus for her is the improvement of survival rates for children with high-risk neuroblastoma, providing more effective treatments with fewer side effects. 

How would you rate this content?

Share this article

Sign up for our monthly Cell Newsletter

You may also be interested in...

Industry Spotlight
Discover the transformative role of AI in the world of biotechnology. Dive deep into its synergy with 3D modeling, revealing groundbreaking advancements in cell & gene therapy and faster, more efficient drug development cycles.
09 October 2023
Industry Spotlight
Adaptimmune has developed from a strategic collaboration with GSK and embarked on a highly successful journey towards developing cancer immunotherapy treatments.
28 September 2023

Continue browsing

Share this article

Join our Cell mailing list

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Cell